HLA Class II Polymorphism and Humoral Immunity Induced by the SARS-CoV-2 mRNA-1273 Vaccine Gutiérrez Bautista, Juan Francisco Sampedro, Antonio Gómez Vicente, Esther Rodríguez Granger, Javier Reguera, Juan Antonio Cobo, Fernando Ruiz-Cabello Osuna, Francisco López Nevot, Miguel Ángel Anti-S antibodies HLA associations mRNA-1273 vaccine This work was supported by "Investigacion y Desarrollo (I + D) del Sistema Andaluz de Salud (SAS)" and Instituto de Salud Carlos III (Proyecto FIS PI21/01708), co-funded by ERDF-FEDER. The vaccines designed against the SARS-CoV-2 coronavirus are based on the spike (S) protein. Processing of the S protein by antigen-presenting cells (APC) and its subsequent presentation to T cells is an essential part of the development of a humoral response. HLA-class II alleles are considered immune response genes because their codified molecules, expressed on the surface of APCs (macrophages, dendritic, and B cells) present antigenic peptides to T cell via their T cell receptor (TCR). The HLA-class II genes are highly polymorphic, regulating what specific peptides induce follicular helper T cells (TFH) and promote B lymphocyte differentiation into plasma or memory B cells. This work hypothesizes that the presence of certain HLA-class II alleles could be associated with the intensity of the humoral response (amount, length) to the SARS-CoV2 mRNA 1273 vaccine. We have studied the relationship between the HLA-class II typing of 87 health workers and the level of antibodies produced 30 days after vaccination. We show a possible association between the HLA-DRB1* 07:01 allele and the HLA-DRB1*07:01~DQA1*02:01~DQB1*02:02 haplotype to a higher production of antibodies 30 days after the administration of the second dose of mRNA-1273. 2022-04-21T11:17:48Z 2022-04-21T11:17:48Z 2022-03-06 journal article Gutiérrez-Bautista, J.F... [et al.]. HLA Class II Polymorphism and Humoral Immunity Induced by the SARS-CoV-2 mRNA-1273 Vaccine. Vaccines 2022, 10, 402. [https://doi.org/10.3390/vaccines10030402] http://hdl.handle.net/10481/74439 10.3390/vaccines10030402 eng http://creativecommons.org/licenses/by/3.0/es/ open access Atribución 3.0 España MDPI